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We cloned the complete complementary DNA of an isolate of the hepatitis C virus, HCV-S1, into a tetracycline-inducible
expression vector and stably transfected it into two human hepatoma cell lines, Huh7 and HepG2. Twenty-six Huh7 and two
HepG2-positive clones were obtained after preliminary screening. Two Huh7 (SH-7 and -9) and one HepG2 (G-19) clones
were chosen for further characterisation. Expression of HCV proteins in these cells accumulated from 6 h to 4 days
posttreatment. Full-length viral plus-strand RNA was detected by Northern analyses. Using RT-PCR and ribonuclease
protection assay, we also detected the synthesis of minus-strand HCV RNA. Plus- and minus-strand viral RNA was still
detected after treatment with actinomycin D. Indirect immunofluorescence staining with anti-E2, NS4B, and NS5A revealed
that these proteins were mostly localised to the endoplasmic reticulum (ER). Culture media from tet-induced SH-9 cells was
separated on sucrose density gradients and analysed for the presence of HCV RNA. Viral RNA levels peaked at two separate
ranges, one with a buoyant density of 1.08 g/ml and another from 1.17 to 1.39 g/ml. Electron microscopy demonstrated the
presence of subviral-like particles (approximately 20–25 nm in diameter) in the cytoplasm of SH-9 and G-19 cells, which were
positively labelled by anti-HCV core antibodies. Anti-E2 antibodies strongly labelled cytoplasmic vesicular structures and
some viral-like particles. Complete viral particles of about 50 nm which reacted with anti-E2 antibodies were observed in the
culture media of tet-induced SH-9 cells following negative staining. Supernatant from tet-treated SH-9 cells was found toINTRODUCTION
Hepatitis C virus (HCV) is an enveloped virus with a
single positive-strand RNA genome of about 9.5 kb (6). It
belongs to the family of Flaviviridae, as a separate genus
from pestiviruses and flaviviruses (35, 43, 57). The HCV
polyprotein is cleaved by both host and viral proteases to
yield structural proteins (core, E1, and E2) and nonstruc-
tural proteins (NS2 to 5B) (46). More than 170 million
people worldwide are infected with HCV (1, 5, 13). About
80% of the infected individuals remain chronically in-
fected for life, of which an estimated 15–20% eventually
develop liver cirrhosis and hepatocellular carcinoma (8).
The understanding of the pathogenesis and replica-
tion of HCV has been hampered by the lack of a satis-
factory cell-culture system which allows efficient propa-
gation of the virus. Numerous groups have reported the
replication of HCV in various human T (38, 39, 54, 55), B
(3, 41, 63), and hepatocytic (17, 22, 51, 59) cell lines using
infected sera as inocula. In addition, HCV-producing79hepatocytic cell lines derived from patients with chronic
hepatitis have also been described (19, 62). Persistent,
long-term HCV-infected cell lines have also been
achieved by transfection of human hepatoma cell line,
Huh7, with a cDNA (15) or in vitro transcribed viral RNA (7,
66). In all these cases, although HCV infection could be
maintained for long periods of time, even up to over a
year (41), viral RNA was not always detectable in the
cells or culture supernatant, suggesting that viral repli-
cation is not very efficient and viral progeny is at best,
intermittently produced (reviewed in 23, 50).
For reasons that are yet unclear, it is difficult to estab-
lish continuous cell lines constitutively expressing full-
length HCV cDNAs (40 and S. P. Lim, personal commu-
nication). This could be attributable to transcriptional
repression, hypermethylation of the transgene, or toxicity
of HCV gene products (28, 34, 40). Recently, the contin-
uous production of inducible HCV proteins from a tet-
repressive system in the osteosarcoma cell line U-2 OS
was described (40). Clones from this cell line allow the
tightly regulated expression of the entire HCV ORF. Nev-infect naı¨ve Huh7 and stable Huh7-human CD81 cells. ©
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tion does not take place in these cells. Attempts to
generate a similar system in the human hepatoma cell
line, Huh7, were apparently unsuccessful (40).
We recently reported the cloning of nine overlapping
cDNA clones covering the entire viral genome of a HCV
isolate (HCV-S1) of genotype 1b including the complete
5 and 3 UTRs (30). We then generated a full-length
genome from these overlapping clones and placed it
under a tetracycline (tet)-inducible promoter in the con-
struct pSTAR (69). This vector offers the advantage of
having incorporated all the features of the rtTAnls system
in one single vector and eliminates the necessity to
establish stable double transfectants normally required
for tet-inducible/repressor systems (69). Following trans-
fection of the human hepatoma cell lines, Huh7 and
HepG2, we obtained stable clones that contained this
full-length HCV genome. These lines can be induced to
express HCV structural and nonstructural proteins. In
addition, these stable cell lines permit replication of HCV
and the production of infectious viral particles. Thus they
maybe potentially advantageous for the study of the life
cycle and molecular biology of the virus and may also be
useful for screening antiviral agents as well as the large-
scale production of viral particles.
RESULTS
Generation and characterisation of tetracycline-
inducible HCV expressing cell lines
We utilized for our cloning the pSTAR vector which
offers the advantage of having incorporated all the fea-
tures of the rtTAnls system for tet induction in one single
vector (69). The HCV genome is cloned under the control
of the promoter TetOmP in pSTAR and is activated by
rtTAnls, which are driven by a CMV promoter and en-
hancer located also in pSTAR (69). Thus transcription of
the HCV genome is mediated by rtTAnls in association
with tet. It has been reported that cloned HCV genome
sequences often harbour deleterious mutations (11).
Since the construction of pSTAR-HCV-S1 involved sev-
eral rounds of cloning, five constructs bearing the full-
length HCV cDNA, HCV-S1 (30, 58), in pSTAR were tested
by transient transfection in 293T cells. To determine if the
HCV proteins would be properly translated, we examined
the expression of core, E2, and NS5A in these clones. All
constructs expressed similar levels of these HCV pro-
teins, 2 and 4 days posttransfection, indicating that the
HCV genomic cDNAs were not defective (Fig. 1). Huh7
and HepG2 cells were then transfected with one of these
pSTAR-HCV-S1 plasmids and selected in G418 for 6 to 8
weeks. Individual clones were picked and screened by
Western analyses. Sixty-six Huh7 clones were obtained
and 26 analysed. All these clones expressed compara-
ble levels of the various HCV proteins upon tet induction,
with little or no basal expression (data not shown). Two
clones, SH-7 and -9, were selected for further analysis. In
the case of HepG2 cells, from 36 clones that were picked
and analysed, only two clones were positive (G-19 and
-22) (data not shown). Clone G-19 was found to express
high levels of HCV proteins and was picked for further
analysis.
A time course was carried out to determine the kinet-
ics of induction of HCV proteins in these lines. HCV
proteins were synthesized as early as 6 h after tetracy-
cline treatment and the levels continued to accumulate
up to 4 days after induction (Figs. 2A and 2B). In both
SH-9 and G-19 cells, we observed that the induced HCV
core protein had a molecular weight of about 16–17 kDa,
corresponding to the mature processed form. Subse-
quently, at 96 h tet-treatment, we were also able to detect
the full-length unprocessed core of about 21 kDa in G-19
cells (Fig. 2B). Interestingly, in G-19 an increase in trun-
cated NS5A products was observed with time (Fig. 2B).
We have demonstrated that HCV core can induce pro-
FIG. 1. Expression of HCV proteins in 293T cells transiently trans-
fected with a pSTAR-full-length (FL) HCV construct after 2 and 4 days
induction with 2 g/ml tetracycline. Cell lysates were separated on
10–12% SDS–polyacrylamide gels, blotted, and incubated with primary
and secondary antibodies as described. Western analyses for the
expression of core (A), E2 (B), and NS5A (C) after transfection with
pSTAR-FL HCV clone 16 are shown (lanes 3–5). Positive controls were
also performed using lysates obtained from 293T cells transfected with
expression constructs for full-length core (A), E2 (B), and NS5A (C) after
2 days (lane 2). Cell lysates from untransfected 293T cells are shown in
lane 1. Arrows indicate the respective HCV proteins. Molecular masses
in kilodaltons (kDa) of protein molecular weight markers are indicated
on the left. Levels of HCV protein expressed were normalised against
endogenous actin levels (D). Results from four other p-STAR FL HCV
clones are similar (data not shown).
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teolytic cleavage of NS5A through a caspase-mediated
mechanism (16). It is highly likely that the truncated
NS5A products seen at the later time points are the
outcome of such an effect. Nevertheless, the protein
levels were maintained for up to 10–12 days post-tet
treatment with little evidence of morphological damage
or cell death in both SH-7, -9, and G-19 cells, suggesting
that the HCV proteins were initially relatively well-toler-
ated by both the hepatoma cell lines (data not shown).
Withdrawal of tet from the culture media after day 8 led
to a gradual shut-down in HCV protein synthesis, sug-
gesting the induction process is reversible (data not
shown). Prolonged culture of the clones in tet beyond
12–15 days, however, did result in increased cell death.
Although the expression of E2, NS3, NS4B, and NS5A
were readily detectable in the two stable Huh7 cells, we
were unable to detect core, E1, and NS5B from 6–48 h.
However all three proteins became detectable after 4
days of tet-treatment (Fig. 2A). The reason for this dis-
parity is unknown but maybe due to a higher turnover of
these proteins in the cells. The expression of these
proteins were readily observed in clone G-19 after 24 h of
tet-treatment (Fig. 2B).
HCV transgenes in stable HCV-inducible cell lines
We next performed Southern analyses to examine the
integration of HCV transgene(s) in the stable hepatoma
clones G-19, SH-7, and -9 (Fig. 3). Plasmid pSTAR-FL HCV
(clone 16) and genomic DNA were digested with EcoRI
and XhoI (Fig. 3A) and probed with the pSTAR FL HCV
construct. In the case of the plasmid DNA, an additional
FIG. 2. Kinetic analyses of expression of HCV proteins in stable human hepatoma cells lines after induction with 2 g/ml tet for a period of 0–96
h. Cell lysates were separated on 10–12% SDS–polyacrylamide gels, blotted, and incubated with primary and secondary antibodies as described. (A)
In stable Huh7 clones, SH-7 and -9, expression of E2, NS3, and NS5A were observed as early as 6 h after tet treatment, while expression of core,
E1, and NS5B were detectable after 96 h. (B) In stable HepG2 clone G-19, expression of core, E1, E2, NS3, NS4B, NS5A, and NS5B were observed
from 6 h after tet treatment and continued to increase 96 h postinduction. Arrowheads indicate positions of the HCV core (A), full-length NS5A (B),
and NS5B (A and B). Molecular masses in kilodaltons (kDa) of protein molecular weight markers are indicated on the left. Levels of HCV protein
expressed were normalised against endogenous actin levels (A and B).
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digest with EcoR5 was also carried out. This digest
produced seven bands, of molecular weights 4.42, 3.00,
2.70, 2.65, 2.30, 2.29, and 0.45 kb. The smallest fragment,
consisting of a 0.45-kb band, had migrated out of the gel
and hence was not observed (Fig. 3A). Similar restriction
patterns were observed for both plasmid and genomic
DNA (Fig. 3A). This suggested that a single copy of the
transgene had integrated into the cell lines, as an addi-
tional band of 5.65 kb would have been observed had
two or more copies of the plasmid integrated into the
FIG. 3. Integration of pSTAR-FL HCV construct in genomic DNA of SH-7 and -9 and G-19 cells. Genomic DNA was extracted from stable
HCV-hepatoma cell lines SH-7, SH-9, and G-19 and analysed by Southern blot hybridisation as described under Materials and Methods. Ten
micrograms of genomic DNA and the indicated amounts of pSTAR-FL HCV plasmid were digested with EcoRI/XhoI (A) or BglI/Bst98I (B). Plasmid DNA
was further digested with EcoR5. All digested DNA were loaded on a 0.8% agarose gel and after blotting were probed with the entire FL HCV construct
labelled with [32-P]dCTP. Arrows indicate positions of digested DNA fragments. Included are schematic representations of the structure of two copies
of HCV transgenes integrated in a head-to-tail manner and the respective digestion pattern obtained after digestion with EcoRI/XhoI (A) or BglI/Bst98I
(B). Thus, an additional 5.65-kb fragment is obtained after digestion with EcoRI/XhoI (A) and a 5.60-kb fragment with BglI/Bst98I digestion (B).
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chromosome in tandem repeats in a head-to-tail fashion
(Fig. 3A). To verify the results observed, we redigested
the DNAs with BglI and Bst98I, which gave rise to three
bands, of molecular weights 13.12, 3.8, and 1.8 (Fig. 3B).
Plasmid DNA was further digested with EcoR5 as before.
Similar to the previous finding, plasmid and genomic
DNAs gave similar restriction patterns (Fig. 3B). No ad-
ditional band of 5.6 kb was obtained, confirming that
indeed only a single copy of the plasmid had integrated
into the chromosome.
Expression of HCV transcripts in stable HCV-inducible
cell lines
To study the expression of HCV transcripts upon tet-
racycline treatment, we carried out Northern blot analy-
ses on the stable cell lines. We also in vitro transcribed
the full-length plus-strand HCV-S1 and included it in our
Northerns as a positive control (Fig. 4). In all three cell
lines, the viral genomic RNA migrated to a similar posi-
tion as the full-length in vitro transcribed (IVT) product
(Figs. 4A and 4B). Full-length viral mRNA was detected in
SH-7, -9, and G-19 cells from 6 h of tet-induction (Figs. 4A
and 4B). In general, the levels of transcripts were lower
in SH-7 and -9 compared to G-19 cells. In the latter, they
increased progressively from 6 h to 4 days after tet
treatment (Fig. 4B). In SH-7, they peaked at 48 h post-tet
addition and declined by day 4, while in SH-9 cells, they
peaked around 24 h (Fig. 4A). We proceeded to assay for
viral replication by using a specific HCV positive-strand
riboprobe that binds minus-strand HCV RNA. Unfortu-
nately we observed only very faint bands at 48 and 96 h
postinduction in the Northern assays (data not shown).
Hence, we turned to the more sensitive RT-PCR, adopt-
ing a strand-specific method devised by Lanford et al.
(29), who used a tagged primer to determine the expres-
sion of minus-strand viral RNA (Figs. 4C and 4D). Plus-
strand RNA was detected as early as 1 h post-tet induc-
tion in all three clones. Minus-strand RNA was also
observed, although the expression was lower than the
plus-strand RNA. In SH-7 and -9 cells, they were found
12 h after tet induction and persisted during the 4 days of
tet-treatment (Fig. 4C). Similarly, minus-strand RNA were
also present from 12–96 h after tet addition in G-19 cells
(Fig. 4D). In contrast, control RNA from Huh7 and HepG2
cells failed to give rise to bands in either the Northern
analyses or the RT-PCR (Figs. 4A–4D).
To ascertain the authenticity of these results, we re-
peated the experiments with actinomycin D (actD) treat-
ment. We first induced G-19 cells with tet for 4 days and
continued the incubation with 32P-labelled UTP, in the
presence or absence of actD for another 24 h. Total
cellular RNA was harvested and Northern hybridized
against plus- or minus-strand full-length IVT HCV-S1 (Fig.
4E). As a control RNA was hybridized against full-length
minus-strand IVT HIV-1 (Fig. 4E). RNA from both un-
treated and actD-treated G-19 cells gave rise to a posi-
tive band with IVT minus-strand HCV-S1 (Fig. 4F, lanes 2
and 6). The signal from untreated cells was much stron-
ger than actD-treated cells. Similarly, a weak but discern-
ible signal was obtained when RNA from untreated and
actD-treated G-19 cells were hybridized against IVT full-
length plus-strand HCV-S1 (Fig. 4F, lanes 4 and 8). In all
cases, no signal was detected when hybridization was
performed with IVT full-length minus-strand HIV-1 (Fig.
4F, lanes 1, 3, 5, and 7). This shows that the binding of
radiolabelled RNA from G-19 cells were HCV specific.
These results indicate that authentic viral RNA synthesis
was taking place in G-19 cells as actD selectively inhibits
transcription from DNA templates but not from RNA tem-
plates.
We next repeated the actD experiments using RNA
obtained from untreated and actD-treated FL-5B-28
cells, a clone which was isolated from stable transfec-
tion of the HepG2 cell line with the construct, pSTAR-
HCV-S1-5B. The latter contains a HCV-S1 genome with
a truncated NS5B sequence and expresses all HCV
structural and nonstructural proteins with the exception
of NS5B (Fig. 4G). We observed a relatively strong band
after Northern hybridization of RNA from untreated FL-
5B-28 cells with IVT minus-strand HCV-S1 (Fig. 4F, lane
10). On the other hand, we failed to detect any signal
after Northern hybridization with IVT plus-strand HCV-S1
(Fig. 4F, lane 12). In addition, FL-5B-28 cells did not
produce any signal with both plus- and minus-strand IVT
HCV-S1 after treatment with actD (Fig. 4F, lanes 14 and
16). These results further show that the hybridization
signals observed in actD-treated G-19 cells were HCV
specific.
Ribonuclease protection assay for HCV minus-strand
RNA in stable HCV-inducible cell lines
Next we carried out ribonuclease protection assay
(RPA) for minus-strand viral RNA using a positive-strand
riboprobe corresponding to the first 221 nucleotides of
the NS3 5 coding sequence. In the G-19 clone, a pro-
tected band similar in size to the probe was obtained
from cells treated with tet for days 2, 5, and 10 (Fig. 4H).
A positive control carried out with full-length negative-
strand IVT HCV-S1 yielded similar results (Fig. 4H, lane
1). Notably, the intensity of the bands increased with the
length of time the cells were induced with tet (Fig. 4H,
lanes 5–7). No band was found in untreated G-19 cells
nor in control tet-treated GSR-1 cells (a stable clone
derived from the HepG2 cell line, bearing the pSTAR
vector) (Fig. 4H, lanes 2 and 3).
Subcellular localisation of HCV proteins
We then proceeded to examine the subcellular local-
isation of HCV proteins in the HCV stable cell lines by
indirect immunofluorescence microscopy. We chose the
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FIG. 4. Northern analyses, RT-PCR, and ribonuclease protection assays for HCV RNA in total cellular RNA from stable HCV-hepatoma cell lines
treated with tet for the indicated times. (A and B) Northern analyses. Detection of full-length HCV plus RNA in SH-7 and SH-9 (A) and G-19 (B) clones
was observed as early as 6 h after tet treatment and comigrated with full-length in vitro transcribed (IVT) HCV RNA. Control RNA from Huh7 (A) and
HepG2 (B) cells failed to give rise to any viral transcript. Levels of HCV RNA were normalised against endogenous GAPDH levels (A and B). (C and
D) RT-PCR. Plus- and minus-strand HCV RNA were detected by Southern hybridisation after RT-PCR of total cellular RNA harvested from SH-7 and
SH-9 (C) and G-19 (D) clones as described. Plus-strand transcripts were detected at 1 h (SH-7, -9, and G-19) post-tet induction while minus-strand
transcripts were detected at 12 h post-tet induction (SH-7, -9, and G-19). (E) IVT. Full length HCV-S1 (2.5 l) plus- (lane 2) and minus- (lane 3) strand
IVT products were run on a denaturing agarose-formaldehyde gel. Lane 4 contains full-length HIV-1 minus-strand IVT product and lane 1 contains
RNA ladder. (F) ActD treatment. Control untreated G-19 (i and ii) or FL5B-28 cells (v and vi) and actD-treated G19 (iii and iv) and FL5B-28 cells (vii
and viii) were extracted for total cellular RNA as described. Hybridisation was performed with IVT full-length HCV-S1 minus- (lanes 2, 6, 10 and 14)
and plus- (lanes 4, 8, 12, 16) strand products as described. As a control, they were also hybridised against IVT full-length HIV-1 minus-strand product
(lanes 1, 3, 5, 7, 9, 11, 13, 15). Membranes were exposed to autoradiographic films for 1 (i), 2 (iii and v), or 5 (ii, iv, vi–viii) days. (G) Western analyses
for FL5B-28 cells showing expression of various HCV structural and nonstructural proteins cultured for 4 days in the absence () or presence ()
of tet. Expression of NS5B was not detected in these cells. (H) RPA for the detection of HCV negative strand in G-19 cells. G-19 cells were induced
with tet over a period of 10 days. RPA was performed using a probe corresponding to the first 221 nt of NS3 coding sequence as described. In vitro
transcribed full-length negative-strand HCV RNA (IVT) was used as a positive control (G–I, lane 1). Control untreated G-19 (lane 4) and GSR-1 (lane
2) cells, tet-treated GSR-1 (lane 3) failed to give rise to the protected band observed in G-19 tet-treated cells (lanes 5–7). A lower exposure of lane
7 is provided (lane 8). Arrows indicate position of full-length viral transcript (A and B), RT-PCR product (C and D), full-length IVT products (E), and the
RPA protected band (H), respectively.
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clone SH-9 for these studies instead of G-19 cells, as the
latter tended to grow in nonadherent clumps which were
not suitable for these studies. With anti-E2, -NS4B, and
-5A antibodies, strong membranous reticular staining
concentrated at the perinuclear regions was observed,
which was characteristic of localisation of these proteins
in the endoplasmic reticulum (Fig. 5, right panel). In the
uninduced cells, only a few cells exhibited a similar
pattern of staining, at much lower levels (Fig. 5, left
panel). Antibodies to core, E1, NS3, and -5B failed to
produce good immunostaining (data not shown).
Capture of viral particles from culture media of
tet-treated SH-9 and G-19
We next assessed the stable lines for their ability to
release viral particles into the cell media. To do this,
we induced SH-9 and G-19 cells with tet for 5 days,
after which the culture media was incubated overnight
FIG. 4—Continued
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with anti-E2 beads. As controls, we used media from
untreated cells. All samples were subsequently
treated with DNaseI and RNaseA after binding to the
beads. Half of the samples were then extracted for
RNA and treated again with DNaseI prior to RT-PCR
analyses. A single strong PCR product of correct size
was obtained in culture media of tet-treated SH-9 and
G-19 cells, but not in uninduced cells (Fig. 6A and B,
lanes 1, untreated and 3, tet-treated). This product was
still present following pretreatment with DNaseI and
RnaseA (Figs. 6A and 6B, lanes 2, untreated and 4,
tet-treated). These results indicate that the PCR prod-
ucts were not due to contaminating viral RNA or plas-
mid DNA present in the culture media, but rather were
derived from encapsidated viral particles that bound to
the anti-E2 antibody beads.
Detection of viral RNA in sucrose density gradients at
two major fractions
To further verify the secretion of viral particles by
tet-induced stable HCV cells, we subjected the culture
media of tet-treated SH-9 to sucrose density gradient
centrifugation and analysed the fractions collected for
viral RNA (Fig. 7). In the fractions we collected from
media of untreated SH-9 cells, we observed only one
band at the density of 1.28 g/ml (Fig. 7A). After tet-
induction for 5 days, we obtained positive PCR bands to
FIG. 5. Indirect immunofluorescence staining of HCV proteins E2 (A), NS4B (B), and NS5A (C) in SH-9 cells after treatment with tet for 5 days. Cells
were prepared for immunostaining as described under Materials and Methods. Control untreated cells gave little background staining (left) while
induced cells showed strong perinuclear staining (right).
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viral RNA at two separate ranges, one with a single peak
at buoyant density of about 1.08 g/ml (fraction 4) and
another that spanned from about 1.17 to 1.39 g/ml (frac-
tions 7–12; Fig. 7B). As a control, we mixed the media
from tet-induced cells with chloroform and performed the
centrifugation as before. Not only did the two positive
ranges disappear, the positive bands also shifted to the
higher range of 1.35–1.43 g/ml, suggesting that chloro-
form had disrupted the envelope of viral particles present
in the fractions of lower densities. We also repeated the
experiment using culture media from tet-treated G-19
cells and obtained similar results (data not shown). To
check the sensitivity of our RT-PCR assay, we repeated
the RT-PCR using decreasing amounts of in vitro tran-
scribed full-length HCV RNA from 100 ng to 0.01 fg. We
observed RT-PCR products only when 100 ng to 1 pg of
IVT RNA was used as template (Fig. 7D). From this
experiment, we conclude that our assay had a detection
limit of about 1 pg or the equivalent of about 105 copies
of viral RNA (Fig. 7D).
Quantification of viral particles in culture media of
tet-treated SH9 cells
We next set out to quantify the amount of viral particles
secreted into the culture media of tet-treated cells, by
employing the Chiron bDNA signal amplification assay
system. Culture media was harvested from tet-treated
and untreated cells, and first treated with DNaseI and
RNaseA to eliminate any contamination from lysed cells.
The culture media was then extracted for RNA and
treated with DNaseI again before being assayed. From
four separate experiments (Table 1, samples A–D), we
obtained an average value of 1–6  105 and 1–3  105
copies/ml of viral RNA in the culture media of SH-9 and
G-19, respectively, after 5 days tet-induction (Table 1).
The control culture media consisting of uninduced SH9
and G-19 cells failed to give detectable viral particles
(Table 1).
Presence of viral-like particles in stable SH9 cells
and its culture media
To investigate if viral particles were indeed made in-
tracellularly, we first carried out transmission electron
microscopy of tet-treated SH9 cells. We observed a rel-
atively abundant number of electron dense spherical
particles of approximately 20–25 nm in diameter located
in the cytoplasm, often along the endoplasmic reticulum
(Fig. 8A). These particles were consistently absent in
control Huh7 and untreated SH9 cells (data not shown).
The localisations in the cytoplasm and appearance of
these particles resemble those of HCV nucleocapsids
reported by other workers (37, 52, 53, 60). We proceeded
to perform immunostaining experiments using anti-HCV
core antibodies on the stable HCV-cell lines. In both
SH-9 and G-19 cells we observed specific immunolabel-
ing in the cytoplasm and cell surface (Figs. 8B–8D).
Furthermore, spherical structures present on the cell
surface (Figs. 8B and 8D) and in the cytoplasm (Figs. 8C
and 8E) were labeled. These structures were mainly
20–30 nm in diameter, although staining of larger struc-
tures (30–50 nm) at the surface were also detected (Figs.
8B and 8D).
We next performed immunolabeling with anti-HCV E2
antibodies. In general we found specific strong labeling
of ER and cytoplasmic vesicular membranous structures
in tet-treated SH9 (Fig. 8F) and G-19 (Figs. 8G and 8H)
cells. This observation is in agreement with that of
Baumert et al. (2). Untreated cells failed to give any
labeling (Fig. 8I). It is believed that HCV virions acquire
their envelope proteins from host intracellular mem-
branes and buds out of the cell via fusion of cytoplasm
vesicles with the plasma membrane (51) and our findings
with these stable cell lines concur with this hypothesis.
Nevertheless, we failed to detect any HCV particles with
enclosed envelopes corresponding to the full viral parti-
cles in SH-9 cells and only a low number in G-19 cells
(Figs. 8G and 8H). One possible explanation for the
absence/low numbers of complete virions may be that
the process of envelope acquisition is slow or transient
and affected by specific cellular host protein(s). We then
checked for viral particles in the culture media from
tet-SH9 cells after fractionation on sucrose density gra-
FIG. 6. Detection of HCV particles in culture media of SH-9 (A) and
G-19 (B) cells after tet-induction. Culture media of untreated (lanes 1
and 2) or tet-treated (lanes 3 and 4) cells were incubated with anti-E2
beads, washed with PBS, and extracted for RNA. In lanes 2 and 4 the
samples were first preincubated with DNaseI and RNaseA before RNA
extraction. RT-PCR was performed as described under Materials and
Methods. Arrows indicate position of RT-PCR band corresponding to
HCV plus-strand RNA.
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dient centrifugation. Complete viral-like particles of ap-
proximately 50 nm were observed by transmission elec-
tron microscopy after negative staining (Figs. 9B–9D).
They were exclusively found in fractions of buoyant den-
sities from 1.08 to 1.15 g/ml, which were also positive for
viral RNA by RT-PCR (Fig. 9A). The nature of these par-
ticles was confirmed by their positive staining with an-
ti-E2 antibodies (Figs. 9E and 9F).
Determination of 5 and 3 ends of HCV transcripts
recovered from sucrose density gradient
centrifugation
As described, the 5 end of the HCV-S1 transcript
contained an additional 6 nt at its 5 UTR and an addi-
tional 8 nt at its 3 UTR. Extraneous nonviral sequences
at either 5 and/or 3 ends of viral genomes have been
reported to be removed during viral replication in cells
and shown to be absent in progeny virus (24, 67, 68). It
has been suggested that this in vivo repair can occur
either through host or viral-encoded exonuclease activi-
ties (24, 67, 68). To investigate whether the extra nucle-
otides added to HCV-S1 RNA were retained or lost in
progeny virions, we sequenced the ends of the RNA
recovered from fractions 1.08–1.11 g/ml of the sucrose
density gradient runs of culture media from tet-treated
SH-9 and G-19. Purified viral RNA was first reverse li-
gated, followed by RT-PCR amplification, and then cloned
as described under Materials and Methods. A band
corresponding to about 195 nt was observed in the
samples after two rounds of PCR amplification (Fig. 10).
FIG. 7. Density distribution of HCV in culture media of tet-induced SH-9 examined by sucrose density gradient centrifugation. Culture media from
untreated (A), tet-treated (B and C) SH-9 cells were loaded on a 20–60% (wt/wt) sucrose gradient and centrifuged as described under Materials and
Methods. Culture media in (C) was first treated with chloroform before being centrifuged. Fractions (500 l) were collected from the tube from the
top and then RT-PCR was performed on each fraction to detect the presence of viral plus RNA as described under Materials and Methods. Ethidium
bromide stained gels of RT-PCR amplified DNA fragments are shown. The buoyant density of each fraction is shown at the top. Arrowhead in (C)
indicates nonspecific bands. The sensitivity of the RT-PCR was determined with decreasing concentrations of in vitro transcribed (IVT) FL HCV
RNA (D).
TABLE 1
Results Obtained from the Chiron bDNA Signal Amplification Assay
to Quantify the Titer of HCV Particles in Culture Media of SH-9 and
G-19, in the Absence of or After 5 Days tet Induction
Cell line
Titer of viral RNA after pretreatment with
DNaseI and RNaseA (105 copies/ml)
Untreated tet (A) tet (B) tet (C) tet (D)
SH-9 NDa 5.1 6.5 1.0 2.0
G-19 ND 1.5 1.0 3 1.3
Note. The Results from Four Separate Experiments are Shown (A–D)
a ND not detected.
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After TA cloning, individual clones were selected for
sequence analyses. Four clones were analysed from
each sample. In all cases, the extraneous sequences at
the 5 and 3 ends of viral RNA were found to be trimmed
from the viral genome.
Infection of naı¨ve Huh7 cells using culture media
from tet-treated stable Huh7 clones
To affirm if the viral particles released infectious, we
collected culture media from SH-9 cells following tet
treatment and layered them onto Huh7 cells, or stable
Huh7 cells expressing the putative receptor for HCV,
CD81 (hCD81). As controls we used culture media from
Huh7 cells expressing the pSTAR vector alone. Viral
plus-strand RNA was detected by RT-PCR in cells lay-
ered with media from tet-treated SH9, but not control
cells (Fig. 11A). In addition, using the strand-specific
method devised by Lanford et al. (29), we also found
negative-strand viral RNA, indicating that viral replication
was taking place. We further observed that stable Huh7-
hCD81 cells expressed more plus- and minus-strand
viral RNAs compared to parental HuH7 cells (Fig. 11A).
To further verify that infection of the Huh7-hCD81 cells
was mediated by HCV virons, we checked if infection
could be abolished by anti-E2 antibodies or recombinant
E2 proteins. First, culture media from tet-treated SH-9
cells was preincubated with protein AG-bound anti-E2 or
human c-myc antibodies before being layered onto
Huh7-hCD81 cells. The experiment was then carried out
as before. Media precleared with anti-E2 but not c-myc
antibodies failed to produce viral infection, as no RT-PCR
bands were obtained for either plus-strand viral RNA
(Fig. 11B, lanes 3 and 4). Next, we preincubated Huh7-
hCD81 cells with recombinant truncated E2 proteins and
repeated the experiment. As was expected, recombinant
E2 completely blocked viral infection as we failed to
obtain any bands after RT-PCR (Fig. 11B, lane 5).
DISCUSSION
We report here the generation of inducible stable
clonal lines from the hepatoma cells, Huh7 and HepG2,
that contain a full-length HCV genome, HCV-S1, bearing
both the complete 5 and 3 UTRs (30, 58). It also in-
cludes the highly conserved 98-nt sequence found on
the extreme 3 end of the viral genome which is believed
to be essential for replication in vivo (25, 65). These
clones synthesized and accumulated HCV proteins fol-
lowing tet-treatment in a time-dependent manner (Fig. 2).
Furthermore viral replication in these stable cells was
demonstrated by treatment of the cells with actinomycin
D (Fig. 4F) and the detection of the presence of negative-
strand RNA using RPA (Fig. 4H) and strand-specific RT-
PCR method (29; Figs. 4C and 4D).
Preliminary electron microscopic work revealed the
presence of electron-dense subviral-like particles (ap-
proximately 20–25 nm in diameter) in the ER and cyto-
plasm of tet-treated SH-9 cells that were absent in the
parental Huh7 or uninduced SH-9 cells (Fig. 8A). These
particles resemble HCV nucleocapsids reported by other
workers (37, 52, 53, 60). Their localisation at the ER within
the cytoplasm as well as their immunolabeling by anti-
HCV core antibodies (Figs. 8B and 8D) support this (37,
52, 53, 60). Although the diameters of the particles (about
20–25 nm) in SH-9 cells were smaller than those re-
ported by other workers (30–35 nm) (37, 52, 53, 60), they
concur with the 20–30 nm viral-like particles (VLPs) pro-
duced in the Pichia pastoris yeast transfected with an
expression construct for the first N-terminal 399 aa of the
HCV polyprotein (9). One plausible reason for this ob-
served disparity in the sizes of VLPs is that the observed
larger VLPs were surrounded by envelope-like structures
derived from either the viral envelope proteins and/or the
cell-membrane components (9). Indeed, following deter-
gent treatment of the VLPs in P. pastoris, the authors
obtained a homogenous population of particles of about
20 nm in diameter (9).
Interestingly, anti-core antibodies showed strong im-
munolabeling on the cell surfaces of tet-treated HCV
cells (Figs. 8C and 8E), including spherical membranous
structures of 30–60 nm in diameter. A recent report has
indicated that nonenveloped HCV nucleocapsids are
found in the serum of HCV-infected patients and chim-
panzees (34). They were rather heterogenous in size,
mainly from 38 to 43 nm in diameter, with some larger 54-
to 62-nm particles (34). It is highly possible that these
spherical structures observed in our HCV-cell lines cor-
respond to HCV nucleocapsids being released from their
cell surfaces. Nevertheless, few complete viral particles
were detected in these HCV cell lines, despite strong
staining by anti-E2 antibodies in the ER and Golgi appa-
ratus (Figs. 8C, 8D, and 8E). The process of envelope
acquisition may be slow or transient and affected by
specific cellular host protein(s), which makes it difficult to
visualize complete virions. In addition, it may also be due
to the technical difficulties as optimal preservations of
cellular and viral structures are critical parameters for
viral visualization (2).
More importantly, these stable cells released infec-
tious viral particles into their culture media after tet-
induction. Viral transcripts were specifically detected in
culture media of tet-treated cells after incubation with
anti-E2 beads (Fig. 6) and were similarly detected by
Chiron bDNA assay kit (Table 1). Complete viral-like
particles of approximately 50 nm were further observed
in the culture media of tet-treated SH-9 cells after su-
crose density gradient centrifugation (Fig. 9). Specifically,
these particles were found only in fractions with buoyant
densities of between 1.08 and 1.15 g/ml, which were
positive for viral transcripts, and in addition, were spe-
cifically immunostained with anti-E2 antibodies (Figs. 9E
and 9F). These findings are in line with the reported low
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buoyant density of HCV particles obtained from HCV-
positive patient sera (14, 21, 36). The sizes of these
complete viral particles concurred with the findings of
other workers where the size of HCV particles were
estimated to be between 30 and 60 nm (12) and 40 and
60 nm (3, 20, 37, 56, 60). Hence, taken together with the
results from the sucrose density gradient centrifugations
and anti-E2 capture experiments, the EM/IEM studies
FIG. 9. Electron microscopy of HCV-like particles in culture media of
tet-induced SH-9 cells. (A) Ethidium bromide stained gels of RT-PCR-
amplified DNA fragments from fractions 1–6 obtained after sucrose
density gradient centrifugation of culture media from tet-treated SH-9
cells. The buoyant density of the fractions are shown at the top. (B–D)
Fractions 4–6 were collected and stained with phosphotungstic acid as
described under Materials and Methods. Viral-like particles of about 50
nm in diameter were observed in these three fractions with buoyant
densities of about 1.08–1.15 g/ml (B to D). The bar indicates 100 nm. (E
and F) Immunogold labeling by anti-E2 antibodies and protein A-gold (6
nm) of viral-like particles (arrows) similar to those observed in (B–D).
The bar indicates 100 nm.
FIG. 8. Electron microscopy of HCV-like subviral particles in tet-
treated SH-9 cells. At 5 days post-tet induction, cells were cryofixed
and processed for electron microscopy as described. (A) Subviral-like
particles of about 20–25 nm in diameter (arrows) were observed adja-
cent to endoplasmic reticulum (ER). Inset shows a higher magnification
of the viral-like particles (arrowheads). Bar indicates 100 nm. (B–F)
Immunogold staining of subviral-like particles (arrows) by anticore
antibodies and protein-gold (10 nm), on cell surface of SH-9 (B) and
G-19 (D) or in the cytoplasm of SH-9 (C) and G-19 (E) cells, affiliated with
membraneous structures (arrowheads). Bar indicates 200 nm. (F–H)
Immunogold labeling by anti-E2 antibodies and protein A-gold (10 nm)
of rough endoplasmic reticulum (ER) in SH-9 (F) and G-19 (G) cells and
Golgi apparatus (GA) in G-19 cells (H). Arrows indicate viral-like parti-
cles. Control untreated cells failed to give any labeling (I). Bar indicates
200 nm.
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provide strong evidence that the stable HCV hepatoma
cell lines are capable of releasing intact HCV particles
into the culture media after tet-treatment.
Huh7 cells have been reported to be capable of sup-
porting HCV replication (50). Human CD81 is a tetras-
panning transmembrane receptor which was previously
shown to interact with the HCV E2 envelope protein (45).
Hence we tested the culture media from tet-induced
SH7-9 and G-19 cells for viral particles by determining
their ability to infect HuH7 and stable HuH7-hCD81 cells.
Culture media from these tet-treated stable cell lines
indeed led to infection of these cells as evidenced by the
presence of plus- and minus-strand viral RNA 5 days
postinfection. We also showed that this infection is me-
diated via enveloped virons as it was specifically inhib-
ited by preincubating the media with anti-E2 antibodies
but not with anti-c-myc antibodies. Moreover recombi-
nant truncated E2 proteins were also capable of prevent-
ing viral infection of naı¨ve unexposed cells.
We believe this is the first report of a inducible system
which allows for the continuous production of infectious
HCV viral particles. An earlier system was described in
which stable osteosarcoma cell lines also expressed
HCV proteins (40). However, these cells did not enable
the assembly of complete viral particles. Besides the
absence of both the viral 5 and 3 UTRs in the viral
transgene, the NS5B protein was also not detected in the
stable clones (40). Stable hepatoma cell lines that allow
high level replication of subgenomic HCV RNAs have
been established (4, 33, 46). In these systems, all the
structural proteins were absent in the HCV subgenomic
replicons and thus would not permit viral replication or
assembly. More recently, transfections of full-length HCV
replicons in Huh7 have also been reported (18, 57),
although HCV viral particle formation was not observed
(57). The authors postulated that Huh7 cells lack host
factors to support viral assembly (57). We have instead
observed viral particle assembly in stable clones derived
from both Huh7 and HepG2 cells. The reason for this
difference is unknown, but unlike the authors who ob-
served different subcellular localization of core and E2
proteins (the former was found mainly on the surface of
lipid vesicles, and the latter was found mainly in the ER),
we detected the presence of both core and E2 in cyto-
plasm and ER of our stable clones. It is possible that the
retention of HCV structural proteins in different cellular
compartments prevented viral assembly in their system.FIG. 10. Reverse ligation of HCV RNA isolated from sucrose density
gradient centrifugation. Culture media from tet-treated SH-9 and G-19
cells were separated on sucrose density gradients and fractions were
collected as described before. Fractions positive for viral RNA were
taken for reverse ligated by T4 RNA ligase and RT-PCR amplified as
described. Ethidium bromide stained gels of RT-PCR-amplified DNA
fragments from the various fractions from tet-treated SH-9 (A) and G-19
cells are shown. Arrows indicate the position of the 195-nt product
obtained. The buoyant density of the fractions are shown at the top of
the lanes (1 and 2). The positions of the DNA markers are shown (M).
FIG. 11. Infection of Huh7 and hCD81-Huh7 cells with culture media
from tet-treated SH-9 cells. (A) Cells that were exposed to culture
media from tet-treated SH-9 cells (lanes 3 and 4) but not untreated cells
(lanes 1 and 2) were positive for viral RNA after RT-PCR analyses.
Stable hCD81-Huh7 showed stronger viral products compared to pa-
rental Huh7 cells. (B) HCV infection of hCD81-Huh7 cells was blocked
by anti-E2 antibodies (lane 4) or recombinant glycosylated E2 proteins
(lane 5), but not with anti-c-myc antibodies (lane 3). In lane 1, hCD81-
Huh7 cells exposed to culture media from untreated SH-9 cells was
used as a negative control. Levels of HCV RNA were normalised
against endogenous actin levels.
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Interestingly, HuH7 cells bearing both HCV sub-
genomic and genomic replicons were reported to re-
lease low levels of low-density structures containing
nuclease-resistant HCV RNA (57). Such membranous
vesicles differ from the viral particles we obtained from
the supernatant of our stable cells in several ways. First,
the viral particles from SH-9 and G-19 cells could be
specifically captured by anti-E2 antibodies (Fig. 6) and
immunostained with anti-E2 antibodies (Fig. 9). Further-
more, using the supernatant from tet-induced SH-9, we
clearly demonstrated reinfection of naı¨ve Huh7 cells
(Fig. 11).
Although numerous groups have demonstrated the
persistent, long-term infected cell lines, these often pro-
duce little HCV proteins, transcripts, and viral particles
(see Introduction). Detection of viral transcripts in many
cases is often inconsistent. Nevertheless, in our system,
the rate of reinfection remains low, as we could only
detect viral transcripts by RT-PCR. This may in part be
explained by the relatively low numbers of viable viral
particles in the culture media (between 1 and 6  105
copies/ml five days postinduction), and as well the in-
herent poorer infectivity of Huh7 cells. By generating a
stable Huh7 cell line expressing human CD81, we were
able to increase the infection efficiency, as demonstrated
by the increased levels of plus and minus transcripts in
these stable Huh7-CD81 cells compared to parental
Huh7 (Fig. 10). Infection could possibly also be enhanced
by collecting culture media from cells treated with tet for
a longer period of time, and/or concentrating the media,
or other mechanisms to enhance viral replication in vivo.
On this note, mutations that occur within the various HCV
nonstructural proteins, such as the NS5A (4, 31), have
been found to confer either increased replicative ability
or cellular adaptation. The incorporation of such advan-
tageous mutations into the backbone of our HCV-S1
clone may serve to enhance viral particle production in
our system. More work needs to be carried out to explore
these various possibilities.
The stable clones reported here could offer a unique
system for studying the molecular biology and life cycle
of the HCV virus, in a cell type that mimicks the natural
infection of HCV in vivo. In so doing, they may serve as
a model to allow us to better understand HCV pathogen-
esis as well as disease onset and progression. In addi-
tion, they may also be useful for the screening of antiviral
agents as well as the large-scale production of viral
particles. Such tet-inducible cell lines are already suc-
cessfully used in drug-screening activities against hep-
atitis B virus (HBV) (26, 27). These cell lines offer the
advantage of being used in a high-throughout, auto-
mated assay system for large-scale evaluation of librar-
ies of candidate anti-HCV compounds. The stable HCV-
expressing clones described here could potentially
serve as a platform for similar endeavours.
MATERIALS AND METHODS
Cells and cell culture
The human embryonic kidney cell line, 293T, which
bears the SV40 large T antigen, and the human hepa-
toma cell lines, Huh-7 and HepG2, were all purchased
from American Type Culture Collection. The cells were
cultured in MEM containing 2 mM L-glutamine, 1.5 g/L
sodium bicarbonate, 0.1 mM nonessential amino acids, 1
mM sodium pyruvate, and 10% fetal bovine serum and
maintained at 37°C in 5% CO2.
Construction of tetracycline-inducible HCV expression
plasmids
The full-length HCV cDNA, HCV-S1, of genotype 1b
(30), was cloned into the plasmid vector, pSTAR (69), in
two steps. First a 3-kb EcoRI-blunted XhoI fragment con-
sisting of nt 6699 to 9609 of HCV-S1 was obtained from
pKSII(NSP9) and cloned into the EcoRI-blunted BamHI
site of pSTAR to generate pSTAR-NSP. Following this, a
6.7-kb EcoRI-EcoRI fragment consisting of nt 341 to
6358 was obtained from pXJ41(S1) (58) and cloned into
the EcoRI site of pSTAR-NSP. Five clones bearing inserts
of the correct orientation were selected. The construct
pKSII(NSP9) contained the fragment from NS2 to 3 UTR
(nt 2428–9609) of HCV-S1 cloned into the SmaI site of
pKSII(/) and contained an engineered EcoRV site 8 nt
downstream from the last nucleotide of HCV-S1 (S. P.
Lim, unpublished results). The plasmid pXJ41(S1) (58)
contained the full-length HCV-S1 cloned into the blunted
NotI and XhoI site of pXJ41neo (70) and an EcoRI site in
front of the 5 UTR of HCV-S1. An EcoRI site was intro-
duced at the 3 end of the CMV promoter in pSTAR so
that transcription initiation results in an additional six
nucleotides at the 5 end of the HCV genome. To gener-
ate the construct pSTAR-FL5B, the sequence from nt
202–1579 of NS5B was deleted from construct pSTAR FL
HCV by digestion with Bst98I and EarI, followed by blunt-
end ligation. This produces a truncated NS5B protein
consisting of only 134 aa. For transfection experiments,
both pSTAR HCV constructs were first linearised with
EcoRV. This results in an additional 8 nt at the 3 end of
the HCV genome.
Sequence analysis
DNA sequencing of all constructs was carried out in
the core facility at the Institute of Molecular and Cell
Biology. Two hundred nanograms of the double-stranded
templates and 10 ng of the primer were used for the
dideoxy method with the Taq DyeDeoxy terminator cycle
sequencing kit and the automated DNA sequencer 373
from PE Applied Biosystems (Foster City, CA).
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Cell transfections
Transfection experiments were performed using Ef-
fectene transfection reagent from Qiagen (Valencia, CA).
Briefly, 2–5  105 cells were plated 14–18 h before and
transfected with 1 g of plasmid DNA according to the
manufacturer’s protocol. Cells were incubated for 48–120
h at 37°C with 5% CO2, after which cells were harvested
for RNA isolation, Western analysis, or treated with 1000
g/ml G418 for selection of stable clones. Media con-
taining G418 were changed every 4–5 days and individ-
ual colonies were picked and expanded for analysis. For
induction of stable cells, 2 g/ml tetracycline was added
for the periods indicated.
Western blot analyses
Protein samples were resolved on a 10 or 12% sodium
dodecyl sulphate (SDS)–polyacrylamide gel, transferred
to a nitrocellulose membrane, blocked with 5% nonfat
skim milk in PBS, and reacted with primary antibodies
followed by anti-mouse or anti-human antibody conju-
gated with horseradish peroxidase (Sigma). Membrane-
bound antibodies were detected with the ECL enhanced
chemiluminescence kit (Pierce). The E2 antibodies, H52,
and H53 were kind gifts from J. Dubuisson (Institut de
Biologie de Lille & Institut Pasteur de Lille, Lille Cedex,
France). H52 recognises a linear epitope with aa 585–
661 of E2, while H53 recognises conformation-depen-
dent epitopes within E2 (10). Both antibodies inhibit the
binding of E2 to CD81-positive cells (10). HCV-S1 bears
84% amino acid homology with HCV-1 in the region
recognised by H52. The NS3 monoclonal antibodies
were purchased from Devaron, Inc. (NJ) and the NS4B
and NS5A monoclonal antibodies were purchased from
Biodesign International (ME). To detect core and NS5B,
sera from HCV-infected patients were used at dilutions of
1:40–1:100. To screen for sera specific against core and
NS5B, we carried out Western analyses with the patient
sera on 293T cells transiently transfected with expres-
sion constructs for core or NS5B. A total of 15 patient
sera samples were tested, three of which were found to
react to NS5B, and at least six were found to react to
core (data not shown).
RNA extraction
Cells were washed twice in phosphate-buffered saline
(PBS) and added with 1.2 ml of the Trizol reagent from
Gibco-BRL and resuspended with a pipette. The mixture
was allowed to stand for 5 min at room temperature (RT),
added with 0.35 ml of chloroform, and inverted for 20 s.
It was incubated at RT for another 5 min and spun at
12,000 rpm for 20 min. The upper phase was transferred
to a new Eppendorf tube, added with 0.8 ml of isopropa-
nol, and mixed by inversion again. The tube was left at
RT for 5 min after which it was spun again at 12,000 rpm
for 20 min at 4°C. The RNA pellet was air-dried and
redissolved in 50 l DEPC-treated water.
Northern analyses
Total cellular RNA was extracted as described above
using Trizol reagent. Thirty micrograms of RNA was run
on 1% formaldehyde-denaturing agarose gels according
to standard protocols. Hybridisation was carried out with
25 ng of 32P-random-primed DNA fragment correspond-
ing to nt 8967–9374 of HCV-S1 in hybridisation buffer
containing 5 SSC, 1 Denhardt’s solution, and 50%
formamide. The filters were incubated at 42°C for 14–16
h, after which they were washed twice at 50°C in 3
SSC–0.1% SDS followed by 0.3 SSC–0.1% SDS. The
filters were then air-dried and exposed to autoradiogra-
phy films at 70°C for 1–2 days.
RT-PCR
Primers for RT-PCR to detect plus- and minus-strand
RNA and GAPDH are listed in Table 2. A 5-l volume of
the RNA isolated from cells was reverse transcribed at
42°C for 30 min using the specific antisense primer and
200 U MMLV RT (New England Biolabs). The cDNA
samples were heated at 100°C for 1 h, followed by
treatment with 2.5 g RNase A for 30 min at 37°C. PCR
was carried out with Taq polymerase (Roche). The first
PCR reaction was performed with 2.5 l of template in a
total volume of 50 l followed by second round of PCR
with 1 l of the first PCR reaction. For the detection of
plus-strand RNA, PCR was performed with P1 and P4,
followed by P2 and P3 or P5. For the detection of minus-
strand RNA, a strand-specific RT-PCR method devised by
Lanford et al. was followed (29). RT was carried out using
the tagged primer, P1-tag (29). The first round of PCR
was carried out with tag and P4 and the second round
with tag and P3 or P5. PCR conditions are as follows:
95°C for 3 min, followed by 30 cycles of 95°C for 20 s,
60°C (for plus-strand) or 49°C (for minus-strand) for 20 s,
72°C for 30 s, and a final extension 72°C for 8 min. In
some instances, 40 cycles of the first-round PCR was
carried to determine the presence of viral transcripts. In
the case of GAPDH, the PCR conditions were 30 cycles
of 95°C for 30 s, 64°C for 30 s, 72°C for 30 s. Amplified
products were visualised by ethidium bromide staining
in a 2.5% agarose gel.
Ribonuclease protection assay
One hundred micrograms of total cellular RNA was
treated with DNaseI (1 U/g RNA) for 2 h at 37°C. RPA
was performed using the RNase protection assay from
Roche (Mannheim, Germany), according to the manufac-
turer’s recommendations. Briefly, RNA was coprecipi-
tated with 32P-labelled probe corresponding to the first
221 nt of NS3 coding sequence (5  105 cpm) and the
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recovered pellet was resuspended in 30 l of hybridisa-
tion solution (40 mM Pipes, 400 mM NaCl, 1 mM EDTA,
80% (v/v) formamide, pH 6.4) at 45°C for 12 h. The
reaction mixture was then treated with RNaseA and
RNase T1, followed by digestion with proteinase K. It was
then extracted with phenol/chloroform/isoamyl alcohol
and precipitated in ethanol. The pellet was resuspended
in 7 l loading buffer (0.1% (v/v) xylene cyanol, 0.1% (v/v)
bromphenol blue, 2 mM EDTA, and 80% (v/v) formamide,
pH 6.4), heated at 95°C for 5 min, and subjected to
electrophoresis in a 6%/7 M urea gel at 30 W for 2.5 h in
Tris–borate buffer. The gel was air-dried and exposed to
autoradiography films at 70°C for 12–24 h. Probe was
labelled by IVT as described below.
Actinomycin D experiment
Cells (2–5 106) were induced with tet for 4 days, after
which they were washed and reseeded. They were then
added with 5 g/ml of actinomycin D (actD) and 200 Ci
of [-32P]UTP for 24 h. As a positive control, tet-treated
cells were incubated with tet and 200 Ci of [-32P]UTP
for another 24 h. Cells were harvested for total cellular
RNA as described. In vitro transcribed full-length plus-
and minus-strand HCV-S1 and minus-strand HIV-1 cDNA
were Northern blotted onto Hybond N membranes
(USB-Amersham). RNA harvested from G-19 cells was
heated at 92°C for 5 min and then hybridised against the
Northern blots in 50% formamide, 5 SSC, 5 Den-
hardt’s solution, and 1% SDS, at 42°C for 12–16 h. The
membranes were washed in 2 SSC and 0.1% SDS at
room temperature, followed by two washes at 60°C and
two washes in 0.5 SSC and 0.1% SDS at 60°C. The
blots were exposed to autoradiography films at 70°C
for 2–5 days.
Southern analyses
To determine the specificity of the products obtained
by PCR amplification, 25 l of the PCR products were
Southern blotted onto Hybond N membrane (USB-Am-
ersham). Hybridisation was carried out with 50 pmol of
32P-end-labelled oligonucleotide corresponding to the 5
NCR of HCV or GAPDH (Table 2) in hybridisation buffer
containing 6 SSC, 1 Denhardt’s solution, and 0.05%
Na pyrophosphate. The filters were incubated at 50°C for
14–16 h, after which they were washed twice at 68°C in
3 SSC–0.1% SDS followed by 0.1 SSC–0.1% SDS. The
filters were then air-dried and exposed to autoradiogra-
phy films at 70°C for 1–2 days. To detect the presence
of the transgene in the stable cell lines, 5  107 cells
were harvested, washed two times in PBS, and digested
overnight at 50°C, with 600 l of digestion buffer (100
mM NaCl, 10 mM Tris–HCl, pH 8, 25 mM EDTA, pH 8,
0.5% SDS) containing 0.1 mg/ml proteinase K. The sam-
ples were extracted twice with phenol/chloroform/
isoamyl alcohol and the genomic DNA precipitated with
0.3 M Na acetate and 2 volume of ethanol. Thirty
micrograms of DNA was digested with the respective
restriction enzymes, run on a 0.8% agarose gel, and
blotted onto Hybond N membranes. Hybridisation was
carried out as above with 25 ng of 32P-random-labelled
probe corresponding to the entire HCV-S1 cDNA.
In vitro transcription
The plasmids pcDNA(S1), containing full-length
HCV-S1 in pcDNA3.1() and pKSII NS3(8), containing
full-length NS3 in pKSII (/) (58), were linearised with
XbaI and BsRGI, respectively. In vitro transcription was
performed with 1 g of each plasmid in the absence or
presence of 50 Ci of [-32P]rCTP using the RiboProbe
in vitro transcription system from Promega (WI) accord-
TABLE 2
Primers for RT-PCR and Southern Hybridisation
Primers Sequence (5-3) Location
P1 ACTCATTCCCATTCTGCAGCTTCC nt 10–28
P2 CTGTGAGGAACTACTGTCT nt 36–55
P3 CGGTGTACTCACCGGTTCC nt 161–143
P4 ACTCGCAAGCACCCTATCA nt 303–285
P5 TCGCGACCCAACACTACTC nt 274–256
P1TAG TCATGGTGGCGAATAAACTCATTCCCATTCTGCAGCTTCC
TAG TCATGGTGGCGAATAA
HCV probe GCAGAAAGCGTCTAGCCATGGCGTTAGTAT nt 68–97
GAPDH FOR CTGAGAACGGGAAGCTTGTCATCAA nt 288–312
GAPDH REV CGTCTAGCTCAGGGATGACCTTGC nt 774–756
GAPDH probe CATTGCTGATGATCTTGAGGCTGTTGT nt 551–525
S1extFOR CTC CAT CTT AGC CCT AGT CAC GG-3 nt 9517–9539
S1intFOR ACG GCT AGC TGT GAA AGG TCC-3 nt 9536–9556
S1extREV GTA CTC ACC GGT TCC GCA GAC-3 nt 167–146
S1intREV CCCGGAGGCTACACGACACTC nt 118–98
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ing to the manufacturer’s recommendations. The DNA
template was removed using RQ1 RNase-Free DNase
(Promega) (1 U/g DNA). The sizes of the IVT products
were checked by visualisation on a denaturing agarose
gel following ethidium bromide staining. The amount of
radioactivity incorporated was determined with the scin-
tillation counter. In vitro transcription of full-length plus-
and minus-strand HCV-S1 was performed with the pcD-
NA(S1) (58) and pcDNA(S1-) (S. P. Lim, unpublished re-
sults), respectively, and that of full-length minus-strand
HIV-1 was performed with pHXB2 (48).
Capture of viral particles from culture media
To determine if viral particles are secreted into the
culture media of tet-induced cells, culture media was
harvested from 1  106 SH-9 or G-19 cells incubated for
5 days with or without tet-induction and clarified at 2000
rpm for 10 min. One-fifth of the media was incubated
overnight at 4°C with protein A/G beads precoated with
approximately 10 g of anti-E2 (H52) antibodies. The
beads were then spun at 14,000 rpm for 5 min and
washed six times with PBS. Beads were then extracted
for RNA by Trizol reagent or first incubated with 10 U of
DNaseI (Promega) and 20 g of RNaseA for 30 min at
37°C followed by treatment with Trizol reagent. The sam-
ples were redigested with DnaseI and analysed by RT-
PCR for HCV transcripts.
Sucrose density gradients
Culture media harvested from 1  106 SH-9 or G-19
cells incubated for 5 days with or without tet-induction
was clarified at 2000 rpm for 10 min and spun at 100,000
g for 14–16 h. The pellet was resuspended in TEN (50
mM Tris–HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, pH 8)
and layered onto a 20–60% (wt/vol) sucrose (in TEN)
gradient and centrifuged at 150,000 g for 72 h at 5°C.
Five hundred microliter fractions were collected from the
top, extracted for RNA, followed by DnaseI treatment,
and analysed by RT-PCR as described. As a control,
culture media from SH9 cells treated with tet was mixed
vigorously with chloroform for 10 min and centrifuged
after the spin at 100,000 g. It was then spun on the
sucrose density gradient and treated as before. The
density of each fraction was determined by refractome-
try.
Determination of 5 and 3 ends of HCV RNA
Viral RNA from fractions obtained after sucrose den-
sity gradient centrifugation were purified as described
above. Viral RNA was ligated with T4 RNA ligase (NEB,
MA) at 37°C for 1 h, followed by RT using primer
S1extREV (Table 2), and two rounds of PCR amplification,
using two sets of primers S1extFOR and S1extREV and
S1intFOR and S1intREV (Table 2). The PCR products
were purified and TA-cloned into pCRII (Invitrogen). The
plasmids were sequenced using M13FOR and REV prim-
ers.
Indirect immunofluorescence
SH-9 cells grown on coverslips were untreated or
treated with tet for 5 days, fixed in 4% paraformaldehyde,
and permeabilized with 0.1% Triton X-100. They were
stained with anti-E2 (H52, diluted 1:40), anti-NS4B
(Biodesign Int, diluted 1:40), and anti-NS5A (Biodesign
Int, diluted 1:40) in 2% BSA in PBS, followed by fluores-
cence isothiocyanate-conjugated anti-mouse antibody
(Sigma) each for 30 min at room temperature. Cells were
washed with PBS between steps. Coverslips were
mounted and immunofluorescence microscopy analyses
performed with a MRC1024 (Bio-Rad) confocal laser
scanning system.
Electron microscopy
Cells were harvested and fixed in 2.5% glutaraldehyde
followed by processing for electron microscopy as de-
scribed in Refs. 42, 44, and 63. Immunoelectron micros-
copy was carried out on cells as described (32, 66). For
analysis of viral particles in fractions from sucrose den-
sity gradient centrifugation, fractions were spun at
150,000 g for 4 h, after which the pellet obtained was
resuspended in 100 l PBS and applied to formvar-
carbon-coated grids and negatively stained with phos-
photungstic acid (20). For immunostaining, one drop of
the sample was adsorbed on a formvar-carbon-coated
copper grid for 10 min at room temperature. It was
incubated on a drop of primary antibody (at dilutions of
1:10 for anti-core (a gift from Michinori Kohara, Tokyo
Metropolitan Institute of Medical Science, Tokyo, Japan)
and 1:20 for anti-E2 (H52) in PBS-BSA) for 30 min, fol-
lowed by rinses on four drops of PBS. It was next incu-
bated on a drop of anti-mouse antibodies for 30 min,
rinsed as before, and incubated with protein A-gold for
15 min. A final wash was carried out twice with PBS and
thrice with water before negative staining with uranyl
acetate.
Infection experiments
The stable line SH-9 was cultured in tetracycline for 5
days, after which the culture media was removed, spun
at 2500 rpm for 5 min, aliquoted, and frozen at 80°C.
Four hundred microliters of culture media was layered
onto 2.5  105 Huh7 cells or stable hCD81-Huh7 cells in
60-mm petri dishes. The full-length CD81 cDNA was
RT-PCR amplified from human spleen cDNA library and
cloned into plasmid pcDNA3.1. Huh7 cells were stably
transfected with this construct and individual clones iso-
lated by selection in G418. Highly expressing CD81-Huh7
clones were isolated by FACscan sorting (Tan et al.,
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unpublished data). Cells were added with 4 ml complete
media and incubated for 6–8 h at 37°C, after which they
were washed six times with PBS, added with 4 ml fresh
media, and reincubated for 5 days at 37°C. At the end of
the period, the supernatant was removed, the cells were
washed two times with PBS, and total cellular RNA was
extracted with the Trizol reagent from Gibco-BRL.
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